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Abstract
AU : Pleaseconfirmthatallheadinglevelsarerepresentedcorrectly:Over 1 million children dev lop tub rculosis (TB) each year, with a quarter dying. Multiple factors
impact the risk of a child being exposed to Mycobacterium tuberculosis (Mtb), the risk of pro-
gressing to TB disease, and the risk of dying. However, an emerging body of evidence suggests
that coinfection with cytomegalovirus (CMV), a ubiquitous herpes virus, impacts the host
response to Mtb, potentially influencing the probability of disease progression, type of TB dis-
ease, performance of TB diagnostics, and disease outcome. It is also likely that infection with
Mtb impacts CMV pathogenesis. Our current understanding of the burden of these 2 diseases in
children, their immunological interactions, and the clinical consequence of coinfection is incom-
plete. It is also unclear how potential interventions might affect disease progression and outcome
for TB or CMV. This article reviews the epidemiological, clinical, and immunological literature on
CMV and TB in children and explores how the 2 pathogens interact, while also considering the
impact of HIV on this relationship. It outlines areas of research uncertainty and makes practical
suggestions as to potential studies that might address these gaps. Current research is ham-
pered by inconsistent definitions, study designs, and laboratory practices, and more consistency
and collaboration between researchers would lead to greater clarity. The ambitious targets out-
lined in the World Health Organization End TB Strategy will only be met through a better under-
standing of all aspects of child TB, including the substantial impact of coinfections.
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Author summary
Over 1 million children develop tuberculosis (TB) each year, and a quarter of a million
children die from this disease. It is increasingly recognised that cytomegalovirus (CMV), a
virus that is very common in young children, especially in communities living in poverty,
disrupts the immune response to the bacteria that cause TB and increases the chance that
a child will develop TB disease. CMV may also change the way that TB manifests in chil-
dren, how easily TB is diagnosed, and influence the outcome of children with TB. Current
research on the interaction between TB and CMV in children is impeded by inconsistent
research approaches and laboratory techniques. In this article, we describe what is known
about TB, CMV, and about how the 2 pathogens interact in children. We then outline the
research gaps that currently exist and make suggestions about the potential studies that
might answer these questions. We believe that a better understanding of the interaction
between these 2 pathogens could have a substantial impact on child health globally.
Introduction
It is estimated that over 70 million children are currently infected with Mycobacterium tuber-
culosis (Mtb) [1], and, each year, 1.2 million children develop tuberculosis (TB) disease [2]. Of
these, a quarter die, representing one of the leading causes of child death globally [1]. Current
public health measures to address childhood TB rely mainly on passive case finding, where
children who have already developed TB disease present to health systems to be diagnosed and
treated. Currently, only about half of the children who develop TB disease are diagnosed [2].
Preventing TB in children would be preferable to waiting for them to become sick.
Although reducing TB exposure is central to preventing childhood TB, approaches that
reduce the risk of progression from infection to disease would also be highly impactful. Condi-
tions that are known to affect T-cell immunity, such as HIV, immunosuppressive drugs, and
malnutrition, have been shown to increase risk of progression from TB infection to disease [3].
Children are regularly exposed to multiple viral and bacterial pathogens, all of which, to some
extent, modulate the developing immune system. It is likely that coinfection with other patho-
gens can impact host susceptibility to, and ability to contain, Mtb [4]. Human cytomegalovirus
(CMV) is one of the most immunogenic viruses that infects children [4–6], and CMV in low-
resource settings is almost universal in early childhood [7,8]. Emerging epidemiological and
immunological evidence suggests that there is a link between CMV infection and progression
to TB disease [9–13]. Although CMV is rarely symptomatic in immunocompetent children,
infection, reinfection, and reactivation of CMV might have extensive implications for the
immunological response to other pathogens, particularly Mtb.
A clearer insight into the immunological interaction between these 2 pathogens could have
profound impacts on TB vaccine development or host-directed therapies. Given the advanced
stage of CMV vaccine development [14,15], it might also be possible to investigate the use of a
CMV vaccine to impact TB infection or progression of disease, at least in the youngest chil-
dren. Understanding the epidemiological and clinical interaction could lead to interventions
that might prevent TB or assist in the diagnosis and treatment of TB in children. In this article,
we review what is known about the epidemiological, clinical, and immunological interaction
between TB and CMV in children and discuss how HIV may impact this relationship. We
then outline areas of uncertainty that require further study and make suggestions as to the type
of studies that could answer some of the remaining questions. Consensus for these research
priorities and future areas for investigation were arrived at through multiple cycles of
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meetings, conference calls, and written feedback among the authorship who bring expertise in
studies of CMV and/or TB in children.
TB
Individuals with infectious TB disease generate aerosolised Mtb that can remain in the air for
long periods. Children in close contact with these TB cases are at high risk of breathing in
bacilli, and, once bacilli reach the terminal alveoli, they are ingested by macrophages. If macro-
phages fail to eradicate the mycobacteria, the adaptive immune system is sensitised, a situation
that can be detected through a tuberculin skin test (TST) or an interferon gamma release assay
(IGRA). If one of these tests is positive, but the child has a normal chest X-ray and has no
symptoms, the child is said to have TB infection. If the mycobacteria proliferate, clinical symp-
toms and signs develop, and the child is said to have TB disease [3].
Epidemiology of TB infection and disease
The prevalence of TB infection increases with age due to cumulative exposure [16]. The rate of
this increase is determined by the force of infection, a reflection of the prevalence of infectious
TB in that context. The risk of progressing from TB infection to TB disease however, has a
more complex interaction with age and is also influenced by gender. Young children are at
high risk of progression from infection to disease, with half of TB-infected infants (<12
months) becoming symptomatic within 12 months. The risk falls rapidly during childhood,
with primary school-age children (from around age 5 years until the onset of puberty) being at
low risk [17]. As individuals enter adolescence, the risk increases, rising first in girls and then
boys [18]. The type of TB that develops is also age dependent. The predominant type of disease
in young children is intrathoracic lymph node disease, either simple enlargement or enlarge-
ment that leads to complications such as bronchial obstruction or erosion into the lung paren-
chyma, causing a pneumonic picture. Young children are also more likely to develop severe
forms of disseminated disease, such as miliary TB or TB meningitis [19]. As children enter
puberty, adult-type disease, with extensive parenchymal involvement and cavities, begin to
predominate.
Immune response to Mtb
Upon internalisation of aerosolised droplets of Mtb into the airways of a new host, the initial
immune response is characterised by an influx of phagocytic cells including resident alveolar
macrophages, lung dendritic cells (DCs), and neutrophils [20]. Mtb bacilli are taken up by a
variety of cell types including DCs, macrophages, neutrophils, monocytes, and epithelial type
II pneumocytes [21]. Infected DCs migrate to the local draining lymph node 8 to 12 days after
infection where they activate antigen-specific T cells and drive differentiation towards an
inflammatory Th1 phenotype [22]. Despite human observational studies and experimental
animal models showing that the Th1 cytokines interferon (IFN)-γ, tumour necrosis factor
(TNF)-α, and interleukin (IL)-12 are critical in protection against acquisition of infection and
progression to TB disease [23,24], these factors alone do not explain the large heterogeneity in
clinical outcomes. More likely is that disease outcome is dependent on many host, pathogen,
and environmental interactions [22].
Immune evasion strategies of TB
Mtb has evolved a variety of immune evasion strategies that have been thoroughly reviewed
elsewhere [25]. Some examples include (1) the capacity of Mtb to block phagosome–lysosome
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fusion by secretion of a lipid phosphatase, SapM, which hydrolyzes phosphatidylinositol
3-phosphate PI3P, a host membrane trafficking regulatory lipid essential for phagosomal mat-
uration and phagosome–lysosome fusion [26]; (2) induction of macrophage production of the
immune regulatory cytokine IL-10, which prevents phagosome maturation and phagolysoso-
mal fusion [22]; (3) ESAT-6 directed sequestration of host beta-2-microglobulin resulting in
the down-regulation of macrophage antigen presentation through MAU : PleasedefineMHCinthesentenceSomeexamplesincludeð1Þthecapacity:::ifapplicable=appropriate:HC Class-I [27]; (4)
lipoarabinomannan (LAM) signalling through alveolar macrophage mannose receptor to
reduce the cellular secretion of pro-inflammatory cytokines TNF-α and IL-1β and chemokines
MCP-1 and IP-10, thereby impairing recruitment of innate immune cells to the lungs [28,29];
and (5) delaying migration of antigen-presenting cells (APCs) to the draining lymph node by
poorly understood mechanisms (by an estimated 3 weeks), resulting in subsequent delays in
T-cell priming [30].
In addition, the bacteria themselves have evolved ways of manipulating the ability of the
host to produce IFN-γ. The early secreted proteins ESAT-6 and CFP-10, which form 2 of the
gene products of a 9.5-kb section of Mtb DNA called Region of Deletion 1 (RD1), are involved
in virulence and pathogenesis of Mtb [31]. ESAT-6 contributes to virulence by inhibiting T-
cell IFN-γ production [32]. An overview of some of these strategies is detailed in Fig 1.
CMV
Epidemiology of CMV infection and disease
Congenital CMV infection, where the virus is transmitted in utero, is a leading cause of perma-
nent hearing loss and neurological impairment as well as vision loss in infants worldwide [33].
Maternal primary infection or reactivation, especially during the first trimester of pregnancy,
is particularly associated with adverse neonatal outcomes [34]. The incidence of congenital
CMV infection is estimated at between 0.7% and 5% of all births in low- and middle-income
countries (LMICs [35]) and approximately 0.3% of births in the United Kingdom [36].
Postnatal CMV acquisition occurs predominantly through breastfeeding and secretions
(e.g., saliva and urine) from infected mothers and siblings. CMV acquired after birth is usually
mild and often asymptomatic; however, the virus establishes lifelong latency, with intermittent
viral reactivation across the life course, which may result in severe complications in immuno-
compromised hosts, such as transplant recipients [37].
The age of postnatal CMV acquisition varies greatly geographically. In LMICs, the preva-
lence of CMV infection is extremely high in childhood and probably universal in infancy, an
important point in light of the risk of progression from TB infection to disease in this age. In a
study in Gambia, 86% of children were infected by the age of 12 months [38]; similar findings
were reported from Uganda, where 95% had immunological evidence of a CMV infection by
the age 5 [11]. By contrast, in the UK, 15% of 1 to 4 year olds, 30% of 20 to 29 year olds, and
approximately 80% of the population was infected by age 65 [39]. Prevalence surveys in other
high-income countries demonstrate a progressive increase in seropositivity with age, with
females consistently having higher rates of seropositivity compared to males in all age groups
[40–42].
Data from the United States show that socioeconomic status is a strong predictor of latent
infection with CMV and other herpesviruses [43].
Immune response to CMV
The immune response to CMV infection is one of the largest ever documented, marked by
persistence of terminally differentiated antigen-specific T cells [44]. Maintenance of CMV in a
latent state is therefore a very resource-intensive activity for the immune system.
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Characterisation of the CMV-specific T-cell population revealed that up to 30% of circulating
CD4+ and CD8+ memory compartments are dedicated to the restraint of viral replication in
CMV seropositive individuals [44], and these percentages may go even higher in the very old
host [45]. This phenomenon, termed “memory inflation,” is linked to permanently high
expression of IFN-γ and other Th1 cytokines to induce a chronic pro-inflammatory state asso-
ciated with immune activation [46] and has been found to correlate with acute phase response
proteins such as C-reactive protein (CRP) [46,47]. While early findings argued that CMV
infection may accelerate natural immune ageing processes [48], subsequent studies showed a
more nuanced picture [49,50]. CMV infection imprints the immune system [51,52], but its
effects on the immune response to vaccines or protection upon experimental infection are
rather modest [53,54]. On the other hand, the immunopathology of chronic inflammation
Fig 1. CMV and TB immune mechanisms of host manipulation. Immune manipulation by CMV (left-hand side), Mtb (right-hand side), and some examples of
possible interactions between the 2 pathogens (centre) in a host cell. Examples of viral genes expressed during both active replication and latent infection aid CMV in
avoiding viral peptides to be displayed on the surface of infected cells. Mtb manipulates cellular machinery to increase or decrease cytokine production and Mtb protein
early secreted antigen (ESAT6) down-regulates presentation of mycobacterial peptides via MHC-I. CMV-derived viral IL-10 may interfere with protection against Mtb,
and CMV-induced immune activation and enhanced type-I IFNs could increase risk and severity of TB disease. While interactions between CMV and Mtb may occur
directly while a host cell is infected with both pathogens, alterations to the wider immunological environment by either pathogen may provide conditions conducive to
pathogenesis by the other. The example of immune manipulation mechanisms shown here is not an exhaustive list. CAU : AbbreviationlistshavebeencompiledforthoseusedthroughoutFigs1and2:Pleaseverifythatallentriesarecorrect:MV, cytomeg lovirus; ER, endoplasmic reticulum;
IFN, interferon; IL, interleukin; MAU : PleasedefineMHCintheabbreviationlistofFig1ifapplicable=appropriate:HC, xxx; Mtb, Mycobacterium tub rcul sis; TAU : Pleasedefin TAPintheabbreviationlistofFig1ifapplicable=appropriate:P, xxx; TB, tu erculosis; TNF, tumor ecr sis factor.
https://doi.org/10.1371/journal.ppat.1010061.g001
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reflects an association of CMV infection with frailty and increased mortality in the elderly,
especially those belonging to lower socioeconomic groups [55–58]. CMV infection is also
linked to long-term cardiovascular disease [59,60] or diabetes mortality [61]. A study of 105
twin pairs, which measured over 200 cellular and serum characteristics, found that most of the
differences in immune parameters were due to nonheritable factors. The authors described
that discordant CMV infection status in monozygotic twins was found to be associated with
differences in 58% of all parameters tested [62]. At the other end of the age spectrum, it has
been shown that CMV infection in infants leads to profound immune dysfunction, specifically
differentiation of the CD8 compartment [4].
While the exact sites of latency are incompletely understood, myeloid lineage cells, includ-
ing monocytes, are well known to harbour silenced CMV genomes during latency [63,64].
Monocytes are not permissive to viral replication, but CMV infection can drive cell differentia-
tion to macrophages [65], which do support the full life cycle of CMV. CMV has a very large
(230 kb) genome, and a multitude of viral genes, expressed during both active and latent CMV
infection, interfere with both innate and adaptive immune responses [66]. These viral genes
will not be reviewed in detail here, but some examples are described in Fig 1 and include genes
that prevent antigen presentation on human leukocyte antigen (HAU : PleasenotethatHLAhasbeendefinedashumanleukocyteantigeninthesentenceTheseviralgeneswillnotbereviewed::::Pleasecheckandcorrectifnecessary:LA) molecules, subvert natu-
ral killer (NAU : PleasenotethatNKhasbeendefinedasnaturalkillerinthesentenceTheseviralgeneswillnotbereviewed::::Pleasecheckandcorrectifnecessary:K) cell r cog i ion of infected cells [66], or void innate antiviral effects by myeloid
cells [67]. For instance, UL111a, a functional homologue to human IL-10 (hIL-10) [68] binds
with high affinity to the hIL-10 receptor despite its low structural homology to hIL-10.
TB–CMV interaction
Spatial and temporal similarities between TB and CMV underscore the biological plausibility
of a hypothetical interaction. Both pathogens infect the same cell types in the same organ, and
both can establish chronic latency in these cells in the lung [69–71]. The very similar age–sex
distribution of the 2 pathogens and the shared risk factors add credence to the idea of an
immunological link between CMV and TB [9]. The interaction between viruses and bacteria is
not a new phenomenon [72]: The associations between HIV and TB have been well docu-
mented, and CMV-associated symptoms, such as retinitis, constitute AIDS-defining illnesses
[1,73,74]. Severe bacterial pneumonia is common following influenza in human populations
[75], and, experimentally, it has been found that mycobacterial growth is enhanced, and sur-
vival is decreased, when mice are exposed to influenza A virus prior to Mtb, in a type I IFN-
dependent pathway [76].
Type I IFNs are key components in antiviral immunity. Syntheses of IFN-α and IFN-β are
rapidly induced after exposure of host cells to CMV [77]. Many viruses have evolved ways to
suppress the antiviral activity of type I IFNs and the 72-kDa IE1 protein (IE1-72 kDa) of CMV
confers partial resistance to these antiviral cytokines [78]. Evidence of both the deleterious and
putative protective role of type I IFNs in TB disease is reviewed by Moreira-Teixeira and col-
leagues [79]. In humans and in mouse models, excessive type I IFNs are also linked to TB dis-
ease exacerbation via an eicosanoid imbalance, whereby necrotic, as opposed to apoptotic, cell
death is induced, resulting in subsequent bacterial escape and further cellular infection [80].
Some examples of overlapping immune manipulation mechanisms of TB and CMV are shown
in Fig 1.
It is important to consider the link between HIV and TB, and HIV and CMV, and the very
likely 3-way interaction between CMV, TB, and HIV [3]. The targeted depletion of TB-specific
CD4+ T cells by HIV [81] highlights the importance of this cell type in particular in the immu-
nological response to TB. T-cell activation and associated pro-inflammatory immune state due
to CMV infection have been demonstrated in people living with HIV [82,83], and repeated
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exposure to Mtb is linked to an augmented activation of T cells [84]. Both these processes likely
lead to HIV disease progression through T-cell activation [85]. CMV is known to imbalance
systemic cytokine, T-cell, and macrophage responses [86], and inflammation caused by either
(re)infection or reactivation could lead to an increased risk of infection with TB or progression
to TB disease [9]. Mouse models suggest that CMV-associated immunosenescence and subse-
quently impaired responses to heterologous infections may be CMV dose dependent [87].
Table 1 summarises the literature in which CMV and TB coinfection has been investigated;
much of the work to date has been done in adults. In a Phase 2b clinical trial of a developmen-
tal TB vaccine, immune activation, characterised by increased HLA-DR on CD4+ T cells, was
associated with increased risk of TB disease in South African infants [12]. As the major driver
of immune variation [62] and a cause of T-cell activation, CMV associations were investigated,
and a positive correlation was found between a CMV-specific IFN-γ response and CD8+ T-
cell activation. In the same infant cohort, and in an adolescent cohort, this CMV profile was
associated with an increased risk of developing TB disease and shorter time to TB diagnosis
[13]. Increased serum IgG to CMV in Ugandan individuals (aged 3 to 56 years) was associated
with increased risk of symptomatic TB disease (odds ratio 2.8 for medium and 3.5 for high IgG
levels) [10], while increased IgG responses to the herpes viruses Herpes Simplex (HSV1/2) and
Epstein–Barr virus (EBV) were not associated with any increased risk of TB disease in the
same cohort [10]. It is hypothesised that repeated exposure (either reactivation or reinfection)
could lead to increased IgG levels (Fig 2). More mechanistic studies are required to determine
if CMV-related changes in the immune system observed in TB are due to an increased replica-
tion of CMV itself or are a manifestation of an altered immune response at large. Investigation
of total IgG levels, which are indicative of nonspecific B cell activation, were not associated
with CMV IgG levels across over 2,000 individuals in rural Uganda [88], nor were they corre-
lated with anti-CMV antibodies among nontuberculous mycobacteria patients or controls in a
study conducted in Australia [89].
Knowledge gaps and how to address them
While CMV may play an important role in the pathogenesis of TB, major areas of uncertainty
exist. In this section, we will highlight specific gaps in the literature and systematic approaches
researchers might use to ensure future studies are efficient and comparable.
Understanding the burden
Little evidence is available concerning the true burden of TB–CMV coinfections. Similar age,
sex, and socioeconomic status distributions exist for both diseases, and they share remarkably
comparable risk factors. Quantifying the prevalence of TB–CMV coinfection on a population
level, by age group, geographical region, and with or without HIV, is crucial to identify risk
factors for infection, disease progression, and poor outcome. As detailed in Table 2, this could
be achieved through cross-sectional surveys and investigation of longitudinal cohorts (ideally
nested within existing cohorts where TB infection and disease status is already characterised).
The latter is especially valuable if regular sampling is included to understand the timing of
CMV and TB infection, as it remains difficult to elucidate which pathogen came first in coin-
fection and what impact that may have. These study designs might include paediatric house-
hold contact studies with a case–control design (CMV positive versus CMV negative), long-
term population-based cohort studies, such as birth cohorts, and vaccine studies.
Diagnostic tools need to be standardised and systematically applied, to allow consistent
reporting across studies. This would include the types of samples taken, sample storage and
laboratory testing, and would include CMV quantitative viraemia (cell-associated and in
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serum to attempt to better understand possible tissue-specific compartmentalisation of CMV),
CMV quantitative serology, and serological avidity. Ideally, the assays used to determine CMV
burden would be able to discriminate between primary CMV infection and reactivation of
Table 1. Studies that have evaluated the interaction between TB and CMV.
Author, year Population Location Type of study Findings
Olaleye, 1990
[90]
Adult TB patients Nigeria Cross-sectional serological study of CMV prevalence
among 161 TB patients, 89 patients other than TB, and
110 healthy donors
Complement fixing antibodies to CMV were higher among






Tanzania Cross-sectional study of cellular IFN-γ responses to
CMV and EBV antigens among 234 TB patients, 213
who survived, and 21 who died at end of treatment
PBMCs from patients who survived (after treatment
completion) exhibited significantly stronger IFN-γ
responses to CMV (p = 0.035), EBV (p = 0.006) or Mtb
ESAT-6 (p = 0.043) at the time of diagnosis as compared to
patients who died during TB treatment. Moreover, 71% of
patients who died were HIV positive, whereas 38% of those
who survived were HIV positive. Analyses were not adjusted
for HIV infection. Immune responses may be an indicator
of general immune fitness and may have been an






Australia Cross-sectional serological study among 112 pulmonary
NTM patients and 117 controls
Elevated levels of CMV antibodies were found in plasma
from patients with pulmonary NTM disease. Exclusion
criteria included HIV infection, excessive alcohol
consumption and smoking. Total IgG levels were






Russia Cross-sectional study of 65 children and adolescents
with respiratory TB
TB cases were 3 times as likely to be infected with CMV
than non-TB individuals. Severity of TB disease was
associated with increased CMV antibody levels compared







Nested case–control study from a Phase 2b efficacy
study of TB vaccine candidate MVA85A. Study included
53 TB case infants and 205 matched controls.
Independent adolescent cohort used to verify findings
Association of activated HLA-DR+ CD4+ T cells and risk of
TB disease. Positive correlation between T-cell activation







Cellular IFN-γ responses to CMV antigens. Same
population as [12]
A CMV-specific IFN-γ response was associated with CD8
+ T-cell activation and increased risk of developing TB
disease and shorter time to TB diagnosis
Stockdale,
2018 [11]
All ages PTB Uganda Cross-sectional serological study of CMV IgG levels in
2,174 individuals in rural Uganda, 27 PTB cases
CMV seropositivity was 83% by 1 year of age, increasing to
95% by 5 years. Female sex, HIV positivity and PTB were




All ages PTB Uganda Cross-sectional serological study of CMV IgG levels in
2,189 individuals in rural Uganda, 27 PTB cases. Same
population as [11]
Higher CMV IgG levels (used as a measure of CMV
exposure) were associated with lower levels of some
antimycobacterial antibodies, but no increase in total IgG.
HIV infection was associated with a decrease in all
antimycobacterial antibodies measured and with an increase
in total IgG. Analyses were adjusted for age and sex
Stockdale,
2020 [93]
All ages Uganda Nested case–control study (nested within [88]) of 25
PTB patients up to 10 years prior to TB diagnosis with 3
to 6 matched controls per case
IgG response to CMV, but not Epstein–Barr or herpes
simplex virus, was associated with increased risk of active
TB disease up to 10 years before diagnosis. Individuals with
medium anti-CMV IgG were 2.8 times more likely to have
PTB (p = 0.055), and those with high anti-CMV IgG 3.4
times more likely to have PTB (p = 0.007). Mycobacterial
antibody levels were not associated with differences in odds
of PTB disease. Nonspecific B cell activation (as measured
by total IgG levels) was not associated with CMV IgG
response
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latent CMV as it is possible that these different forms of CMV could have different impacts on
TB disease progression. For TB diagnostics, improved approaches for both TB infection and
TB disease are required. For TB infection, more advanced assays for pathogen detection, in
addition to immunological sensitisation are needed [94,95], as are tools to determine viable
bacilli that are likely to cause future disease [96,97]. For TB disease, microbiological evalua-
tions using traditional respiratory specimens require optimisation, and newer diagnostics,
using biomarkers in blood and urine, should be applied [98,99]. Finally, modelling studies
could help to estimate burden and mortality from TB–CMV coinfections, given the number of
cases, the proportion diagnosed, and expected mortality in treated and untreated individuals.
Effect sizes can be used to not only quantify the effect of CMV infection on TB, but also esti-
mate the impact of a CMV vaccine on TB incidence.
Fig 2. Conceptual framework of TB and CMV interaction in low- and high-risk children. Conceptual framework of
TB and CMV interaction in high-and low-risk children. Black arrows represent CMV infection, reactivation, or
reinfection events. Red dashed lines show hypothesised CMV viral load following infection, reactivation, or reinfection
events. Blue line represents IgG antibody levels to CMV. Lower risk child—immune competent children aged
approximately between 4 and 15. Higher risk children—children aged less than 4 years old, immune compromised,
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A previous study, from a predominantly adult cohort, shows that the odds of progressing to
TB disease in individuals with medium (of 3 levels) and high CMV IgG levels were 1.8 and 3.4,
compared to those with low CMV IgG levels [10,93]. To understand the excess risk attributed
to CMV (or the percentage of TB cases that could be averted if CMV exposure were reduced/
removed from the population), we calculated the population attributable fraction (also called
the risk difference or excess risk) [100]. To derive a rough estimate of population attributable
fractions for having raised CMV IgG levels, odds ratio data from Stockdale and colleagues [93]
and the equation pc(ψ – 1)/ψ were used, where pc is the proportion of risk factor among cases
only, and ψ is the odds ratio [101]. With the caveats that these estimates are from limited data
and are not in a paediatric setting, among rural Ugandan individuals with a medium level (of 3
levels) of CMV IgG as measured by ELISA (1.04 to 1.34 OD units), 25% of the TB cases in that
group could be attributed to having a raised level of CMV IgG. Among individuals with high
CMV IgG levels (1.35 to 2.84 OD units), 32% of the TB cases in that group could be attributed
to having a raised level of CMV IgG. The study used here is cross-sectional, and multiple cov-
ariants may have influenced the apparent associations. Additionally, more work is needed to
tease apart the relationship between CMV IgG levels, extent of CMV infection, CMV infection
that could be avoided by giving a CMV vaccine, and the possible ramifications of that on TB
infection and disease progression.
Another possibility is that CMV is impacting upon the protective effect of BCG, the only
available TB vaccine. It remains difficult to estimate if, and how, CMV might affect the
response to a TB vaccine, as we do not have a clear correlate of protection for TB, neither vac-
cine induced nor acquired via infection. Effects of CMV on other vaccine responses have been
described previously but remain unclear. For influenza vaccine, both up- and down-regulation
of immune responses vaccines have been described [102,103], and the response to an Ebola
vaccine is pronouncedly reduced in CMV–positive adults [104]. How this might translate to a
Table 2. Understanding the burden for CMV–TB interaction.
Question Knowledge gap (summary) Potential study designs Parameters and samples to be evaluated
How prevalent are CMV–
TB coinfections, and what
are risk factors for these
infections?
- Quantifying the burden, timing, and
outcome of TB–CMV coinfections across
different sites and in different risk groups-
Impact of co-factors on CMV–TB
prevalence- Identifying individual risk
factors associated with TB–CMV
coinfection- Identifying individual
characteristics associated with poor
outcome
- Systematic review of existing literature-
Cross-sectional and longitudinal cohorts
(observational, diagnostic, and randomised
intervention studies in humans nested
within well-characterised TB cohorts) to
quantify prevalence and risk factors for
CMV–TB coinfection- Modelling studies to
evaluate the number of deaths from TB–
CMV coinfections, given number of cases,
the proportion diagnosed, and expected
mortality treated and untreated
Acute versus latent infection (CMV)- Viral
detection: whole blood (EDTA) for viral
load (PCR), respiratory specimen, and
others- Serology (plasma/serum):
quantitative IgG, IgM, and IgG avidity
TB diagnostic workup:- TB microbiology-
Immunoassays evaluating T-cell response-
Novel biomarkers in blood and urine
How do TB, CMV, and
HIV interact?
- Impact of HIV on prevalence of CMV–TB
coinfections and disease course- Impact of
CMV in HIV-infected on TB progression
and clinical presentation- Impact of CMV–
TB coinfection on course of HIV
- In vitro models including isolated cell
populations and mechanistic models-
Observational, diagnostic, and randomised
intervention studies in humans- In vivo
models including mouse and nonhuman
primate coinfection- Longitudinal cohorts
from varying geographical areas and with
different patient populations
Acute versus latent infection (CMV)- Viral
detection: whole blood (EDTA) for viral
load (PCR), respiratory specimen, and
others- Serology (plasma/serum):
quantitative IgG, IgM, and IgG avidity-
Evidence for exacerbation of TB disease or
activation of latent TB infection in CMV/
MTB coinfected animals
TB diagnostic workup:- TB microbiology-
Immunoassays evaluating T-cell response-
Novel biomarkers in blood and urine
HIV- Viral detection: whole blood (PCR)-
CD4 and CD8 T-cell count (absolute, %)
CMV, cytomegalovirus; PCR, polymerase chain reaction; TB, tuberculosis.
https://doi.org/10.1371/journal.ppat.1010061.t002
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TB vaccine remains unclear; any modelling would need to be informed by prospectively col-
lected data to derive realistic models.
Understanding the underlying pathogenesis
The limited number of studies investigating both CMV and TB together point towards over-
lapping epidemiology and analogous risk factors. Equally, mechanistic studies of each patho-
gen individually present a sound biologic hypothesis for an interaction. There remains a major
gap in our understanding of the underlying pathophysiology, and very little has been published
in this field (Table 1). However, a recent study has demonstrated that CMV-associated
immune activation may play an important role in the pathogenesis of TB in children [12];
immune activation, characterised by increased HLA-DR on CD4+ T-cells, was associated with
increased risk of TB disease in South African infants [12,13].
As detailed in Table 3, we suggest that studies could be undertaken, assessing mechanisms
by which either CMV or TB could exacerbate the other, taking into consideration the impact
of TB disease on CMV reactivation, and the impact of CMV on response to TB infection, dis-
ease progression, and response to treatment.
In addition to clinical investigations, animal and in vitro coinfection models could be
important to define early stages of infection and interaction and to highlight mechanistic rela-
tionships. There are no established animal models to study CMV–TB interaction to date. The
major animal models used for Mtb are the mouse, guinea pig, and nonhuman primate,
although a wide range of models have been used for TB including zebra fish, rabbit, rats, mini
pigs, and cattle [105].
In the case of CMV, the guinea pig (GPCMV) or rhesus macaque (RhCMV) CMV models
are most commonly used [106]. Human CMV is host restricted and typically does not infect
animal tissue; therefore, rodent-specific CMV strains are used to investigate the pathogenesis
of CMV in mouse, rat, and guinea pig, and primate-specific strains are used to investigate
Table 3. Understanding the underlying pathogenesis and immunology of CMV–TB interaction.
Question Knowledge gap (summary) Potential study designs Parameters and samples to be evaluated
Does CMV impact the
host response to Mtb,
and, if so, by which
mechanisms?
- Mechanisms through which CMV impacts
acquisition of, and progression to, TB
disease (or vice versa)- Evaluation of effects
of one infection on the immune response to
the other (direct versus indirect)-
Mycobacterial or viral characteristics:
impact of different strain types of Mtb/
CMV on disease pathogenesis- Role of
CMV reactivation during TB disease and its
effect on the response to TB treatment
- In vitro models including isolated cell
populations and mechanistic models-
Mechanistic models based on both animal
models and human specimens from affected
populations to study underlying
mechanisms, but also as a tool for evaluation
of further hypothesis- Immunological studies
characterising immune response (esp. T-cell
response and activation; host omics—
transcriptomics, proteomics, and
metabolomics)
Animal model- Dynamics of T-cell and
antibody responses specific for CMV and
MTB in coinfected animals- Quantification of
CMV and MTB in lung, spleen, lymph nodes,
and other tissues of coinfected animals-
Impact of CMV on myeloid inflammatory
responses in animal models
Human model/specimen (for TB and CMV):-
T-cell response and activation; whole blood/
PBMCs- Host omics (transcriptomics,
proteomics, and metabolomics); whole blood
Acute versus latent infection (CMV)- Viral
detection: whole blood (EDTA) for viral load
(PCR), respiratory specimen and others-
Serology (plasma/serum): IgG, IgM
TB diagnostic workup:- TB microbiology-
Immunoassays evaluating T-cell response
Does CMV impact the
natural history and
pathogenesis of TB?
- Correlation between CMV DNA and
progression to TB disease- Impact of
relative timing of CMV and TB infection on
disease progression- Description of relative
risk of TB progression in CMV–
seropositive children
- Observational studies in humans-
Longitudinal cohorts from varying
geographical areas and with different patient
populations to characterise which patients
develop CMV–TB coinfections (risk factors)
Acute versus latent infection (CMV)- Viral
detection: whole blood (EDTA) for viral load
(PCR), respiratory specimen and others-
Serology (plasma/serum): IgG, IgM
TB diagnostic workup:- TB microbiology-
Immunoassays evaluating T-cell response
CMV, cytomegalovirus; PCR, polymerase chain reaction; TB, tuberculosis.
https://doi.org/10.1371/journal.ppat.1010061.t003
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infection in rhesus macaques [107,108]. Although CMV infections are highly species specific,
human CMV is closely related to the CMV seen in nonhuman primates with a high sequence
homology of approximately 97% [106,109,110], making the rhesus macaque a good candidate
for an animal model in which TB–CMV coinfection could be studied. However, as RhCMV
circulates naturally in nonhuman primate (NHP) colonies, natural exposure at birth can con-
found infection studies with RhCMV. Therefore, as the mouse model has been used exten-
sively to investigate both Mtb and murine cytomegalovirus (MCMV) separately it might have
utility for the early investigation of the interactions between TB and CMV before progression
to larger animal models. The advantage of the mouse model for exploring TB–CMV coinfec-
tion is the tractability of this model for exploration of immune mechanisms with the wide
availability of different strains, gene knockouts, and immune reagents. There are standardised
mouse models for the exploration of Mtb infection, and the mouse model is routinely used for
assessing TB vaccine and drug efficacy [111]. Although MCMV infection does not mirror the
clinical aspects of human CMV infection, there are parallels, in particular the strong and sus-
tained immune activation and CD8+ T-cell memory inflation driven by the MCMV Smith
strain in the mouse, which is a parallel of the inflated HCMV memory response in humans
[112]. Also, in parallel with human CMV, the lung in mice is a reservoir of latent MCMV
infection and frequently the site of viral reactivation, which drives inflammation and can cause
pulmonary fibrosis [113]. Mouse models of TB–CMV will be of particular value when ques-
tions are focused on clinical and immunological observations from human studies. Examples
of human in vitro models are outlined in Table 3.
Understanding clinical impact
Primary CMV infection and reactivation are often linked to poor long-term health outcomes.
In bacterial sepsis, CMV reactivation (similar to other herpesviruses) is associated with worse
clinical outcomes (including mortality) as well as longer duration of mechanical ventilation
[114–116]. For individuals with HIV, simultaneous CMV infection has been shown to impact
HIV disease progression and severity of disease, and an independent correlation between
CMV DNA viral load and AIDS-defining events has been described [117,118]. In addition, the
age-adjusted relative risk of progression to AIDS was 2.5 times higher in CMV–seropositive
compared to CMV–seronegative individuals [119].
In Table 4, we highlight the importance of determining the direct relationship between
CMV infection and severity of clinical presentation of TB, in addition to the possible relation-
ship between CMV infection and other TB risk factors such as malnutrition or HIV. By char-
acterising the coinfection status of CMV, TB, and HIV in clinical cohorts, it would be possible
to determine whether CMV is a predictor for mortality or morbidity in TB.
For CMV, there are few tools to differentiate between primary infection, reactivation, and
recent reinfection (with the same or a new CMV strain). Stages of disease in TB pathogenesis
are similarly difficult to classify, particularly in the absence of reliable diagnostic tools. In
Table 4, we recommend the systematic measurement of both CMV viral load and serology
(IgG, IgM, and IgG avidity) ideally in a range of stored samples from well-characterised TB
cohorts to increase the comparability between studies. Use of biobanked samples from well-
characterised cohorts could also facilitate the discovery of new and reliable tools and testing
approaches to study coinfections and might be an efficient initial approach.
Interventions
Ultimately, if a link is found, the research outlined in this article should facilitate the identification,
evaluation, and implementation of effective interventions. A number of CMV vaccines are
PLOS PATHOGENS
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currently under evaluation, targeting the prevention of congenital CMV or post-transplant infec-
tion (recently reviewed by Plotkin and colleagues [15]). While there are no Phase III data available
yet, early evidence from Phase II studies suggest that a vaccine could reduce CMV infection in
seronegative individuals by 43% to 50%, compared to placebo groups [15]. In addition, several
interventions requiring cultural rather than programmatic changes have been described, such as
parenting practices or handwashing to reduce or at least delay CMV transmission [122–124].
Another area that that might lead to substantial impact is in the field of biomarkers to predict
future TB disease progression. If studies can identify easily measurable CMV-associated predictive
signatures of TB progression, interventions could be targeted at high-risk children.
Interventions or programmatic changes, ideally optimising and interlinking current pro-
grammes on TB/CMV control and outcome, could be either targeted at populations at large,
or at specific subgroups, such as HIV–positive children with chronic lung disease (Table 5).
As CMV is ubiquitous, the aim of those would not necessarily be to prevent, but rather delay,
infection. If CMV infection increases the risk of acquisition of primary TB infection or pro-
gression from infection to disease, then a delay in CMV infection might have an enormous
effect, especially considering that most children dying from disease are very young. Disease
modelling work from Knight and colleagues on the effect of TB vaccines has shown that a vac-
cine with even a moderate efficacy of 60% would avert a total of 17 million TB cases by 2050,
especially when targeting adolescents and adults [125]. This and other modelling studies
[126,127] highlight the potential impact of interventions, even if efficacy is suboptimal.
Exploring TB and CMV infection and immune responses within TB and CMV vaccine trial
cohorts could determine whether these (and other) coinfections effect efficacy or immunoge-
nicity of novel vaccine candidates. Determining whether the CMV infection is a primary infec-
tion or reactivation might inform which CMV vaccine could be used. Again, to make maximal
use of a well-characterised cohorts, collection and storage of a wide range of clinical samples
for more basic research purposes should be incorporated.
Table 4. Understanding the clinical impact of CMV–TB interaction.




Morbidity:- Frequency of severe clinical
presentation in CMV–positive versus CMV–
negative children- Association of CMV
positivity with other morbidities that
influence TB presentation (HIV and
malnutrition)
Mortality:- Identifying individual
characteristics associated with poor outcome-
Quantify the burden and outcome of TB–
CMV coinfections across different sites and in
different risk groups- CMV as predictor for
mortality in TB
- Systematic review of existing literature-
Autopsy studies of deaths from clinical TB/
pulmonary infections, etc.- Observational,
diagnostic, and randomised intervention
studies in humans- Longitudinal cohorts from
varying geographical areas and with different
patient populations to characterise which
patients develop CMV–TB coinfections (risk
factors)- Using biobanked clinical samples
from TB cohorts
Acute versus latent infection (CMV)- Viral
detection: Whole blood (EDTA) for viral load
(PCR), respiratory specimen and others-
Serology (plasma/serum): IgG, IgM
TB diagnostic workup:- TB microbiology-
Immunoassays evaluating T-cell response
Human model/specimen (for TB and CMV):-
T-cell response and activation; whole blood/
PBMCs- Host omics (transcriptomics,
proteomics, and metabolomics); whole blood
How does CMV
affect the way child
TB is diagnosed?
- Reliable and feasible reference standards for
both CMV and TB- Impact of CMV on
disease presentation and diagnosis of children
with TB- Diagnostics needed:
• Pathogen-based (nuclei amplification,
antigen, amd metabolites)




- Observational, diagnostic, and randomised
intervention studies in humans
• New tests and testing approaches for CMV
and TB evaluated in longitudinal cohorts from
varying geographical areas and with different
patient populations
• Adequately designed and powered STARD
[120,121] compliant multi-centre diagnostic
evaluations• Biobanking of well-characterised
samples to aid discovery and evaluation of
novel diagnostics
Acute versus latent infection (CMV)- Viral
detection: Whole blood (EDTA) for viral load
(PCR), respiratory specimen and others-
Serology (plasma/serum): IgG, IgM
TB diagnostic workup:- TB microbiology-
Immunoassays evaluating T-cell response
Human model/specimen (for TB and CMV):-
T-cell response and activation; whole blood/
PBMCs- Host omics (transcriptomics,
proteomics, and metabolomics); whole blood
CMV, cytomegalovirus; PBMC, peripheral blood mononuclear cell; PCR, polymerase chain reaction; TB, tuberculosis.
https://doi.org/10.1371/journal.ppat.1010061.t004
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The way forward
Epidemiologic and immunologic evidence exists for an interaction between TB and CMV. Bet-
ter data are required to confirm a direct link, to understand the scope of the relationship, and
elucidate mechanisms of CMV–TB coinfection. Part of our poor understanding stems from
inconsistent and nonstandardised definitions and testing processes. There is a need for head-
to-head comparisons of the existing and new assays for diagnostic tests for both pathogens,
particularly for CMV. As yet, there is no consensus on the sample type or assays to be used. If
we could diagnose and classify these 2 diseases in a consistent way so that all researchers are
speaking the same language, then shared biological pathways could be identified and appropri-
ate interventions planned. Armed with potential drug therapies, vaccines, and sociobeha-
vioural interventions, appropriate studies could be designed to evaluate them, with adequate
sample size and clearly defined endpoints. Once the efficacy of interventions is established,
implementation in LMIC settings will be challenging, but, increasingly, there is recognition
that complex health interventions can be implemented in any context [128–130]. Good exam-
ples are the widespread delivery of infant vaccines and increasingly universal antiretroviral
therapy access. The ambitious targets set by the World Health Organization in their End TB
Strategy to reduce TB deaths by 95% and to cut new cases by 90% between 2015 and 2035 will
only be met by addressing all aspects of TB, including the impact of coinfections such as CMV.
The challenges for child and adolescent TB are substantial, and an improved understanding of
the relationship between CMV and TB may be key to reducing morbidity and mortality in this
age group.
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